Schering’s sugammadex gets panel review
Executive Summary
Schering-Plough's selective relaxant binding agent Bridion (sugammadex) will be reviewed by FDA's Anesthesia and Life Support Drugs Advisory Committee on March 11. The drug is under priority review for reversing neuromuscular blockade by certain muscle relaxants used in general anesthesia, and FDA action is expected in the second quarter. This is the first open new product review for the Anesthesia panel since 1999...